<DOC>
	<DOCNO>NCT02914665</DOCNO>
	<brief_summary>This phase 2 randomize , double-blind , placebo-controlled study evaluate cardiac renal effect short term treatment elamipretide patient hospitalize congestion due heart failure</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Cardiac Renal Effects Short Term Treatment With Elamipretide Patients Hospitalized With Congestion Due Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>A history chronic heart failure least 1 month Treated ≥40 mg/day furosemide bumetanide ≥1 mg/day torasemide ≥10 mg/day least 1 month Inhospital observation/admission treatment ≤72 hour primary cause admission heart failure persistent congestion opinion Investigator ( i.e . least +2 pit oedema and/or estimate 8 kg gain weight baseline past 4 week ) require intravenous loop diuretic therapy Sufficiently severe oedema justify treatment intravenous infusion furosemide 10 mg/hour least 48 hour Systolic blood pressure &gt; 90 mmHg consider haemodynamically stable , opinion Investigator History leave ventricular ejection fraction ( LVEF ) ≤40 % confirm last 18 month NTproBNP &gt; 1500 pg/ml BNP &gt; 500 pg/ml An eGFR &gt; 30 mL/min/1.73 m2 use eGFR ( mL/min/1.73 m2 ) = 175 x ( Scr ) 1.154 x ( Age ) 0.203 x ( 0.742 female ) x ( 1.212 African American ) Acute coronary syndrome , stroke , transient ischemic attack ( TIA ) , coronary peripheral revascularization procedure , valve procedure , OR major surgical procedure within previous 6 week Invasive cardiac investigation and/or treatment ( i.e . coronary angiography , percutaneous coronary intervention [ PCI ] surgery ) surgical procedure plan next 4 week Use intravenous radiographic contrast agent within 72 hour prior screen plan use study Severe , investigator opinion , uncorrected valve disease congenital heart disease cause cardiac decompensation Acute mechanical cause decompensated heart failure papillary muscle rupture Obstructive infiltrative cardiomyopathy ( e.g . amyloid , sarcoid , etc ) , suspect acute myocarditis , heart failure relate untreated metabolic condition ( e.g . haemochromatosis ) Second third degree heart block unless subject ventricular pacemaker Atrial fibrillation/flutter sustain ventricular response &gt; 130 bpm Placement ventricular resynchronization device within previous 6 week Treatment plan treatment intravenous inotropic agent digoxin time admission Receipt intravenous vasodilator therapy ≤ 6 hour prior randomization The presence mechanical assist device list history heart transplant Severe respiratory disease anticipate need mechanical respiratory support ( i.e . mechanical ventilation ) Anuric previous 24 hour Haemoglobin &lt; 9 g/dL screening plan blood transfusion next 30 day Serum potassium &gt; 5.5 mEq/L Marked proteinuria suggestive nephrotic syndrome Estimated GFR ( eGFR ) per MDRD equation &lt; 30 ml/min Serum albumin &lt; 2.8 g/dL Liver enzymes ( alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] ) elevation &gt; 5 time upper limit normal ( ULN ) Total bilirubin &gt; 2.0 time ULN absence Gilbert 's Syndrome Current plan ultrafiltration , paracentesis , haemofiltration dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>diuresis</keyword>
	<keyword>dropsy</keyword>
	<keyword>congestion</keyword>
	<keyword>elamipretide</keyword>
	<keyword>MTP-131</keyword>
	<keyword>Bendavia™</keyword>
</DOC>